• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管紧张素 II 是否对 SARS-CoV-2 产生反应峰?

Does Angiotensin II Peak in Response to SARS-CoV-2?

机构信息

Laboratório de Biologia Celular e Tecidual, Programa de Pós-Graduação em Biologia Celular e Molecular, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS, Porto Alegre, Brazil.

Programa de Pós-Graduação em Biotecnologia (PPGBiotec), Programa de Pós-Graduação em Ciências Médicas (PPGCM), Universidade do Vale do Taquari-UNIVATES, Lajeado, Brazil.

出版信息

Front Immunol. 2021 Jan 14;11:577875. doi: 10.3389/fimmu.2020.577875. eCollection 2020.

DOI:10.3389/fimmu.2020.577875
PMID:33519802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7842149/
Abstract

Human infection by the SARS-CoV-2 is causing the current COVID-19 pandemic. With the growing numbers of cases and deaths, there is an urgent need to explore pathophysiological hypotheses in an attempt to better understand the factors determining the course of the disease. Here, we hypothesize that COVID-19 severity and its symptoms could be related to transmembrane and soluble Angiotensin-converting enzyme 2 (tACE2 and sACE2); Angiotensin II (ANG II); Angiotensin 1-7 (ANG 1-7) and angiotensin receptor 1 (AT1R) activation levels. Additionally, we hypothesize that an early peak in ANG II and ADAM-17 might represent a physiological attempt to reduce viral infection tACE2. This viewpoint presents: (1) a brief introduction regarding the renin-angiotensin-aldosterone system (RAAS), detailing its receptors, molecular synthesis, and degradation routes; (2) a description of the proposed early changes in the RAAS in response to SARS-CoV-2 infection, including biological scenarios for the best and worst prognoses; and (3) the physiological pathways and reasoning for changes in the RAAS following SARS-CoV-2 infection.

摘要

人类感染 SARS-CoV-2 是导致当前 COVID-19 大流行的原因。随着病例和死亡人数的不断增加,迫切需要探索病理生理学假说,试图更好地了解决定疾病进程的因素。在这里,我们假设 COVID-19 的严重程度及其症状可能与跨膜和可溶性血管紧张素转换酶 2(tACE2 和 sACE2);血管紧张素 II(ANG II);血管紧张素 1-7(ANG 1-7)和血管紧张素受体 1(AT1R)的激活水平有关。此外,我们假设 ANG II 和 ADAM-17 的早期峰值可能代表一种降低病毒感染 tACE2 的生理尝试。这一观点提出:(1)简要介绍肾素-血管紧张素-醛固酮系统(RAAS),详细说明其受体、分子合成和降解途径;(2)描述 SARS-CoV-2 感染后 RAAS 的早期变化,包括最佳和最差预后的生物学情景;(3)SARS-CoV-2 感染后 RAAS 变化的生理途径和推理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/ef9fcf37415a/fimmu-11-577875-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/b399c1c69dc7/fimmu-11-577875-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/33440420daf8/fimmu-11-577875-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/ef9fcf37415a/fimmu-11-577875-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/b399c1c69dc7/fimmu-11-577875-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/33440420daf8/fimmu-11-577875-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/7842149/ef9fcf37415a/fimmu-11-577875-g003.jpg

相似文献

1
Does Angiotensin II Peak in Response to SARS-CoV-2?血管紧张素 II 是否对 SARS-CoV-2 产生反应峰?
Front Immunol. 2021 Jan 14;11:577875. doi: 10.3389/fimmu.2020.577875. eCollection 2020.
2
Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.可溶性 ACE2 在重症 COVID-19 合并症患者中的潜在有害作用。
Rev Med Virol. 2021 Sep;31(5):1-12. doi: 10.1002/rmv.2213. Epub 2021 Jan 10.
3
Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.了解肾素-血管紧张素-醛固酮-SARS-CoV 轴:全面综述。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00912-2020. Print 2020 Jul.
4
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.SARS-CoV-2 利用血管紧张素转换酶 2 进入细胞进行复制的机制概述:与肾素-血管紧张素系统相关的可能治疗选择。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053.
5
The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.免疫系统、肾素-血管紧张素-醛固酮系统(RAAS)与 RAAS 抑制剂之间的相互作用可能会调节 COVID-19 的转归:系统评价。
J Clin Pharmacol. 2021 Aug;61(8):987-1000. doi: 10.1002/jcph.1852. Epub 2021 Apr 7.
6
Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study.评估 SARS-CoV-2 患者血管紧张素转换酶 2(ACE2)、血管紧张素 II(Ang II)、miR-141-3p 和 miR-421 水平:一项病例对照研究。
BMC Infect Dis. 2024 Apr 22;24(1):429. doi: 10.1186/s12879-024-09310-3.
7
Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19.血管紧张素 II 在 COVID-19 康复者中加剧了针对 SARS-CoV-2 的 T 细胞反应。
Int J Mol Sci. 2022 Aug 4;23(15):8669. doi: 10.3390/ijms23158669.
8
Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.肾素-血管紧张素-醛固酮系统与 SARS-CoV-2 相互作用的内无序观点。
Infect Genet Evol. 2020 Nov;85:104510. doi: 10.1016/j.meegid.2020.104510. Epub 2020 Aug 24.
9
Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries.新型冠状病毒介导的死亡率和靶器官损伤中 ACE(血管紧张素转换酶)-2 和肾素-血管紧张素肽的失调。
Hypertension. 2022 Feb;79(2):365-378. doi: 10.1161/HYPERTENSIONAHA.121.18295. Epub 2021 Nov 30.
10
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.血管紧张素 II 的升压剂量对 ACE2 及与 SARS-CoV-2 感染相关的其他分子在小鼠体内没有影响。
FASEB J. 2021 Mar;35(3):e21419. doi: 10.1096/fj.202100016R.

引用本文的文献

1
ACE2, a therapeutic target of COVID-19, needs to be treated with caution.血管紧张素转换酶2(ACE2)作为新型冠状病毒肺炎(COVID-19)的一个治疗靶点,需要谨慎对待。
Arch Virol. 2025 May 29;170(7):143. doi: 10.1007/s00705-025-06327-0.
2
Oxidative stress in patients with coronavirus disease and end-stage renal disease: a pilot study.新型冠状病毒病合并终末期肾病患者的氧化应激:一项初步研究。
BMC Nephrol. 2024 May 4;25(1):155. doi: 10.1186/s12882-024-03584-0.
3
Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study.

本文引用的文献

1
Human recombinant soluble ACE2 in severe COVID-19.严重新型冠状病毒肺炎中的人重组可溶性血管紧张素转换酶2
Lancet Respir Med. 2020 Nov;8(11):1154-1158. doi: 10.1016/S2213-2600(20)30418-5. Epub 2020 Sep 24.
2
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.ACE2/ADAM17/TMPRSS2 相互作用可能是 COVID-19 的主要风险因素。
Front Immunol. 2020 Oct 7;11:576745. doi: 10.3389/fimmu.2020.576745. eCollection 2020.
3
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells.
评估 SARS-CoV-2 患者血管紧张素转换酶 2(ACE2)、血管紧张素 II(Ang II)、miR-141-3p 和 miR-421 水平:一项病例对照研究。
BMC Infect Dis. 2024 Apr 22;24(1):429. doi: 10.1186/s12879-024-09310-3.
4
The Eye of the Storm: Investigating the Long-Term Cardiovascular Effects of COVID-19 and Variants.风暴之眼:探究 COVID-19 及变体的长期心血管影响。
Cells. 2023 Aug 27;12(17):2154. doi: 10.3390/cells12172154.
5
SARS-CoV-2 and Hypertension: Evidence Supporting Invasion into the Brain Via Baroreflex Circuitry and the Role of Imbalanced Renin-Angiotensin-Aldosterone-System.严重急性呼吸综合征冠状病毒2与高血压:支持通过压力反射回路侵入大脑的证据以及肾素-血管紧张素-醛固酮系统失衡的作用
Neurosci Insights. 2023 Feb 1;18:26331055231151926. doi: 10.1177/26331055231151926. eCollection 2023.
6
Severe acute respiratory syndrome coronavirus 2 may cause liver injury Na/H exchanger.严重急性呼吸综合征冠状病毒2可能导致肝脏损伤 钠/氢交换体。
World J Virol. 2023 Jan 25;12(1):12-21. doi: 10.5501/wjv.v12.i1.12.
7
Role of the extracellular matrix in COVID-19.细胞外基质在新型冠状病毒肺炎中的作用
World J Clin Cases. 2023 Jan 6;11(1):73-83. doi: 10.12998/wjcc.v11.i1.73.
8
Adamalysins in COVID-19 - Potential mechanisms behind exacerbating the disease.COVID-19 中的 Adamalysins - 加重疾病的潜在机制。
Biomed Pharmacother. 2022 Jun;150:112970. doi: 10.1016/j.biopha.2022.112970. Epub 2022 Apr 15.
9
Thromboprophylaxis in COVID-19 - Rationale and considerations.COVID-19 相关的血栓预防——基本原理和注意事项。
Adv Biol Regul. 2021 Aug;81:100819. doi: 10.1016/j.jbior.2021.100819. Epub 2021 Jul 23.
TMPRSS2 和 furin 均是 SARS-CoV-2 在人呼吸道细胞中蛋白水解激活所必需的。
Life Sci Alliance. 2020 Jul 23;3(9). doi: 10.26508/lsa.202000786. Print 2020 Sep.
4
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.阐明可溶性血管紧张素转换酶2在新型冠状病毒肺炎中的争议性风险效益概况。
Crit Care. 2020 Jul 6;24(1):396. doi: 10.1186/s13054-020-03097-w.
5
Genomewide Association Study of Severe Covid-19 with Respiratory Failure.全基因组关联研究严重新冠肺炎伴呼吸衰竭。
N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17.
6
Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.SARS-CoV-2 对 CD8 细胞的选择性减少与 COVID-19 患者的预后不良和全身炎症有关。
Clin Immunol. 2020 Aug;217:108486. doi: 10.1016/j.clim.2020.108486. Epub 2020 May 29.
7
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.COVID-19 中的细胞因子风暴:发病机制和治疗中使用的抗炎药物概述。
Clin Rheumatol. 2020 Jul;39(7):2085-2094. doi: 10.1007/s10067-020-05190-5. Epub 2020 May 30.
8
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.COVID-19 中的免疫反应:通过靶向 SARS-CoV-2 触发的途径来应对药理学挑战。
Signal Transduct Target Ther. 2020 May 29;5(1):84. doi: 10.1038/s41392-020-0191-1.
9
Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.血管紧张素转换酶2(ACE2)在2019冠状病毒病(COVID-19)预防和管理中的潜在作用
J Transl Int Med. 2020 May 9;8(1):9-19. doi: 10.2478/jtim-2020-0003. eCollection 2020 Mar.
10
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对成人 SARS-CoV-2 感染的风险和影响:一项实时系统评价。
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.